Cardiac morbidity following modern treatment for Hodgkin lymphoma: Supra-additive cardiotoxicity of doxorubicin and radiation therapy

References

• Boivin J F, Hutchison G B, Lubin J H, Mauch P. Coronary artery disease mortality in patients treated for Hodgkin's disease. Cancer 1992; 69: 1241–1247
   PubMed Web of Science ®Google Scholar
• Glanzmann C, Kaufmann P, Jenni R, Hess O M, Huguenin P. Cardiac risk after mediastinal irradiation for Hodgkin's disease. Radiother Oncol 1998; 46: 51–62
   PubMed Web of Science ®Google Scholar
• Boivin J F, Hutchison G B. Coronary heart disease mortality after irradiation for Hodgkin's disease. Cancer 1982; 49: 2470–2475
   PubMed Web of Science ®Google Scholar
• Hancock S L, Tucker M A, Hoppe R T. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 1993; 270: 1949–1955
   PubMed Web of Science ®Google Scholar
• King V, Constine L S, Clark D, Schwartz R G, Muhs A G, Henzler M, et al. Symptomatic coronary artery disease after mantle irradiation for Hodgkin's disease. Int J Radiat Oncol Biol Phys 1996; 36: 881–889
   PubMed Web of Science ®Google Scholar
• Swerdlow A J, Higgins C D, Smith P, Cunningham D, Hancock B W, Horwich A, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst 2007; 99: 206–214
   PubMed Web of Science ®Google Scholar
• Hull M C, Morris C G, Pepine C J, Mendenhall N P. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA 2003; 290: 2831–2837
   PubMed Web of Science ®Google Scholar
• Reinders J G, Heijmen B J, Olofsen-van Acht M J, van Putten W L, Levendag P C. Ischemic heart disease after mantlefield irradiation for Hodgkin's disease in long-term follow-up. Radiother Oncol 1999; 51: 35–42
   PubMed Web of Science ®Google Scholar
• Abrahamsen A F, Loge J H, Hannisdal E, Nome O, Lund M B, Holte H, et al. Late medical sequelae after therapy for supradiaphragmatic Hodgkin's disease. Acta Oncol 1999; 38: 511–515
   PubMed Web of Science ®Google Scholar
• Chronowski G M, Wilder R B, Tucker S L, Ha C S, Younes A, Fayad L, et al. Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy. Int J Radiat Oncol Biol Phys 2003; 55: 36–43
   PubMed Web of Science ®Google Scholar
• Aleman B M, van den Belt-Dusebout A W, De Bruin M L, van ‘t Veer M B, Baaijens M H, de Boer J P, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007; 109: 1878–1886
   PubMed Web of Science ®Google Scholar
• Kinsella T J, Ahmann D L, Giuliani E R, Lie J T. Adriamycin cardiotoxicity in stage IV breast cancer: possible enhancement with prior left chest radiation therapy. Int J Radiat Oncol Biol Phys 1979; 5: 1997–2002
   PubMed Web of Science ®Google Scholar
• Pihkala J, Saarinen U M, Lundstrom U, Virtanen K, Virkola K, Siimes M A, et al. Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation. Eur J Cancer A 1996; 32: 97–103
   Web of Science ®Google Scholar
• Valagussa P, Zambetti M, Biasi S, Moliterni A, Zucali R, Bonadonna G. Cardiac effects following adjuvant chemotherapy and breast irradiation in operable breast cancer. Ann Oncol 1994; 5: 209–216
   PubMed Web of Science ®Google Scholar
• Fine J P, Gray R J. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496–509
   Web of Science ®Google Scholar
• Booth G L, Hux J E, Fang J, Chan B T. Time trends and geographic disparities in acute complications of diabetes in Ontario, Canada. Diabetes Care 2005; 28: 1045–1050
   PubMed Web of Science ®Google Scholar
• Apter S, Shemesh J, Raanani P, Portnoy O, Thaler M, Zissin R, et al. Cardiovascular calcifications after radiation therapy for Hodgkin lymphoma: computed tomography detection and clinical correlation. Coron Artery Dis 2006; 17: 145–151
   PubMed Web of Science ®Google Scholar
• Heidenreich P A, Hancock S L, Lee B K, Mariscal C S, Schnittger I. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol 2003; 42: 743–749
   PubMed Web of Science ®Google Scholar
• Adams M J, Lipsitz S R, Colan S D, Tarbell N J, Treves S T, Diller L, et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 2004; 22: 3139–3148
   PubMed Web of Science ®Google Scholar
• Zinzani P L, Gherlinzoni F, Piovaccari G, Frezza G, Bendandi M, Ferretti R M, et al. Cardiac injury as late toxicity of mediastinal radiation therapy for Hodgkin's disease patients. Haematologica 1996; 81: 132–137
   PubMed Web of Science ®Google Scholar
• Canellos G P, Anderson J R, Propert K J, Nissen N, Cooper M R, Henderson E S, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327: 1478–1484
   PubMed Web of Science ®Google Scholar
• Ferme C, Eghbali H, Meerwaldt J H, Rieux C, Bosq J, Berger F, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 2007; 357: 1916–1927
   PubMed Web of Science ®Google Scholar
• Eich H, Mueller R, Engert A, Hansemann K, Skripnitchenko R, Pfistner B, et al. Comparison of 30 Gy versus 20 Gy involved field radiotherapy after two versus four cycles ABVD in early stage Hodgkin's lymphoma: interim analysis of the German hodgkin study group trial HD10. Int J Radiat Oncol Biol Phys 2005; 63(s2)1
   Web of Science ®Google Scholar
• Fuchs P, Borchmann P, Dietlein M, Eich H, Müller H, Pfistner B, et al. The new trial generation of the German Hodgkin study group (GHSG). Haematologica 2007; 92(s5)7
   Google Scholar
• André M, Raemaekers J, Van der Maazen R, Reman O, Van ‘t Veer M, Lutgenburg E. The H10 EORTC/GELA randomized intergroup trial on early FDG-PET scan guided treatment adaptation versus standard combined modality treatment in patients with supradiaphragmatic Stage I/II Hodgkin's lymphoma. Haematologica 2007; 92(s5)7
   Google Scholar
• Johnson P, Federico M, Enblad G, Burton C, Smith P, Qian W. Respose-adapted therapy using PDG-PET scanning after initial ABVD: the UK, NCRI, Italian and Nordic trial in advanced Hodgkin lymphoma. Haematologica 2007; 92(s5)7–8
   Google Scholar
• Girinsky T, van der Maazen R, Specht L, Aleman B, Poortmans P, Lievens Y, et al. Involved node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 2006; 79: 270–277
   PubMed Web of Science ®Google Scholar
• Heidenreich P A, Schnittger I, Strauss H W, Vagelos R H, Lee B K, Mariscal C S, et al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease. J Clin Oncol 2007; 25: 43–49
   PubMed Web of Science ®Google Scholar
• Koh E-S, Tran T H, Heydarian M, Sachs R K, Tsang R W, Brenner D J, et al. A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: reduction in normal tissue dose and second cancer risk. Radiation Oncol 2007; 2: 13
   PubMed Web of Science ®Google Scholar